Zach Hartman
Latest Articles
Marker Therapeutics Exits ASH An Optimist. Should That Be Enough For You?
Cancer Research Highlight: AstraZeneca's Checkpoint Combo Fails To Help In Head And Neck
Cancer Research Highlight: Curtains Begin To Close On AbbVie's Small Cell Program
Cancer Research Highlight: Puma Biotech's Basket Pays Off
Cancer Research Highlight: Bristol-Myers And Seattle Genetics Put The Full Court Press On Aggressive Lymphoma
Cancer Research Highlight: BeiGene Also Showed Up At ASH With Potentially Crucial Checkpoint Data
BeiGene Mounts Its Assault On The Ibrutinib Hegemony
Cancer Research Highlight: ImmunoGen's Heme Program Rumbles Under The Surface
Cancer Research Highlight: Astellas Takes Us Into A New Generation Of Therapy For AML
Cancer Research Highlight: Bristol's Barnstorm Of Bad News Clouds Their Hopes In Small Cell Lung Cancer
Cancer Research Highlight: Daiichi Sankyo Joins The AML Blitz
Cancer Research Highlight: AbbVie And Pfizer Blitz Acute Myeloid Leukemia
Cancer Research Highlight: Merck KGaA Gets Into Deeper Trouble In Immune Checkpoint Inhibition
Cancer Research Highlight: Exelixis Sweeps The Leg In A Rare Tumor Group
Kura Oncology: A Primer For Investors Heading Into 2019
Cancer Research Highlight: AstraZeneca Finally Fulfills The Premonitions Of Ill Fate In NSCLC
Cancer Research Highlight: Blueprint Medicines Lets Loose In GIST
Cancer Research Highlight: RedHill Biopharma Sets Up Continued Invasion Into Cancer
Cancer Research Highlight: Nektar Posts An Encouraging SITC Report
Cancer Research Highlight: Pfizer Looks To Re-Enter The ALK Race
Cancer Research Highlight: OncoSec Attempts To Pivot Off 'Negative' Results
Cancer Research Highlight: AVEO Oncology Hatches Its Big Breakout In Kidney Cancer
Advaxis, Revisited
Cancer Research Highlight: Geron Looks To Get Digging Out Of 2018
Cancer Research Highlight: Genmab Continues To Storm Into Frontline Myeloma
Cancer Research Highlight: PARP Inhibition Sets A New Benchmark For Ovarian Cancer
Cancer Research Highlight: Merck Takes Its Big Swing At Kidney Cancer
Cancer Research Highlight: Roche Prepares Another Assault On Early Breast Cancer
Cancer Research Highlight: Yet Again, It's Bristol Drawing The Short Stick In Lung Cancer
A Company In Decline? The Case For/Against Affimed After Bad News
AVEO Pharmaceuticals Enters A Critical Juncture Amid Stock Market Uncertainty. Will Its TKI-That-Could Prevail?
Alpine Immune Sciences: Digging Into A Recent Newcomer Onto The Immunotherapy Scene